Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTHNASDAQ:FRTXNASDAQ:GTBPNASDAQ:NLSP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.17-5.6%$0.16$0.12▼$4.55$1.41M-0.141.25 million shs1,024 shsFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsGTBPGT Biopharma$2.57-4.8%$2.36$1.72▼$4.10$6.65M1.48244,833 shs30,980 shsNLSPNLS Pharmaceutics$2.25-3.8%$1.60$1.30▼$18.39$8.42M-0.21872,976 shs111,972 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path0.00%-5.56%+25.83%-5.45%-90.86%FRTXFresh Tracks Therapeutics0.00%0.00%0.00%0.00%+6.25%GTBPGT Biopharma-6.88%-11.07%+6.20%+7.98%-27.20%NLSPNLS Pharmaceutics-3.85%+21.62%+52.85%+22.28%+1,196.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path1.5185 of 5 stars3.50.00.00.00.60.01.3FRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma3.574 of 5 stars3.85.00.00.03.30.81.3NLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 3.00Buy$20.0011,664.71% UpsideFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00328.02% UpsideNLSPNLS Pharmaceutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56GTBPGT BiopharmaN/AN/AN/AN/A$5.42 per shareN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%N/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AGTBPGT Biopharma-$7.60M-$5.69N/AN/AN/AN/A-257.47%-131.09%8/13/2025 (Estimated)NLSPNLS Pharmaceutics-$12.17MN/A0.00∞N/AN/AN/AN/AN/ALatest BPTH, FRTX, NLSP, and GTBP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86FRTXFresh Tracks TherapeuticsN/AN/AN/AGTBPGT BiopharmaN/A1.451.45NLSPNLS PharmaceuticsN/A0.15N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%FRTXFresh Tracks Therapeutics25.04%GTBPGT Biopharma8.15%NLSPNLS PharmaceuticsN/AInsider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%FRTXFresh Tracks Therapeutics0.23%GTBPGT Biopharma10.90%NLSPNLS Pharmaceutics16.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path108.31 million5.73 millionOptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableGTBPGT Biopharma82.59 million1.99 millionNo DataNLSPNLS Pharmaceutics63.60 million3.01 millionNot OptionableBPTH, FRTX, NLSP, and GTBP HeadlinesRecent News About These CompaniesNLS Pharmaceutics to present Mazindol study at ASCP MeetingMay 23, 2025 | investing.comNLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual MeetingMay 21, 2025 | prnewswire.comNLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal ModelsApril 15, 2025 | prnewswire.comNLS Pharmaceutics, Kadimastem announce up to $3M equity financingApril 1, 2025 | markets.businessinsider.comNLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility AgreementMarch 31, 2025 | accessnewswire.comNLS Pharmaceutics CEO Issues Letter to ShareholdersMarch 10, 2025 | prnewswire.comNLS Pharmaceutics announces new preclinical data for AEX-2February 27, 2025 | markets.businessinsider.comNLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist PlatformFebruary 27, 2025 | prnewswire.comNLS Pharmaceutics and Kadimastem complete pre-IND diabetes meeting with FDAFebruary 25, 2025 | markets.businessinsider.comKadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes TreatmentFebruary 25, 2025 | prnewswire.comNLS Pharmaceutics files $75M mixed securities shelfFebruary 11, 2025 | markets.businessinsider.comNLS and Kadimastem to merge, aim for diabetes care innovationFebruary 10, 2025 | msn.comNLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 TherapiesFebruary 10, 2025 | prnewswire.comNLS Pharmaceutics files to sell 645,161 common shares for holdersFebruary 5, 2025 | markets.businessinsider.comNLS Pharmaceutics AG (NLSP) Stock: Analyzing Its Quiet PowerFebruary 3, 2025 | bovnews.comKadimastem Ltd.: Kadimastem Shareholders Approved the Merger with NLS PharmaceuticsJanuary 31, 2025 | finanznachrichten.deNLS Pharmaceutics’ merger approved by Kadimastem shareholdersJanuary 31, 2025 | markets.businessinsider.comNLS Gains on Deal with KardimastemJanuary 31, 2025 | baystreet.caNLS and Kadimastem move forward with merger plansJanuary 31, 2025 | msn.comNLS Pharmaceutics Stock Rises 29% Following Merger Announcement With KadimastemJanuary 31, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTH, FRTX, NLSP, and GTBP Company DescriptionsBio-Path NASDAQ:BPTH$0.17 -0.01 (-5.56%) As of 05/30/2025 03:42 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Fresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.GT Biopharma NASDAQ:GTBP$2.57 -0.13 (-4.81%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.72 +0.16 (+6.03%) As of 05/30/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.NLS Pharmaceutics NASDAQ:NLSP$2.25 -0.09 (-3.85%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.17 -0.08 (-3.33%) As of 05/30/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
